CNMV

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

Retrieved on: 
Friday, September 16, 2022
Adult, Multiple sclerosis, Safety, CNMV, EVOLUTION, EudraCT, Ageing, AD, Data monitoring committee, Aggression, Mercado, Amnesia, Patient, Clinical trial, Suicide, Government budget balance, Communication, Time, ISIN, ORY, Sale, Mouse, Person, Public expenditure, Lists of diseases, Prospectus, Neuroinflammation, Particle-size distribution, Borderline personality disorder, COVID-19, Degenerative disease, Forward-looking statement, ESCAPE, Genomics, BPD, GLOBE, Spanish, Agitation, Conference, Mission statement, LSD1, Self-harm, Schizophrenia, Program, MS, Mental health, Moderate, Kabuki syndrome, CNS, BDP, Pharmaceutical industry, Phase

Blinded aggregate safety data presented at ECMH correspond to the initial randomized 43 patients (data cut-off, 30 June 2022).

Key Points: 
  • Blinded aggregate safety data presented at ECMH correspond to the initial randomized 43 patients (data cut-off, 30 June 2022).
  • In July 2022, the independent Data Monitoring Committee for PORTICO reviewed the available safety data and determined that the trial should continue.
  • Oryzons oral communication at ECMH is entitled PORTICO, a double-blind, randomized placebo-controlled, adaptive Phase IIb trial with vafidemstat in Borderline Personality Disorder.
  • Currently, vafidemstat is in two Phase IIb trials in borderline personality disorder (PORTICO) and in schizophrenia patients (EVOLUTION).

Sapena buys 25,000 Lleida.net shares

Retrieved on: 
Thursday, September 1, 2022
Euronext Growth, EPA, OTCQX, CNMV, BME Growth, Union, BME, LLN, GLOBE, Invention, Growth, Subpoena, Online gambling, Renewable energy, Airline

MADRID, Spain, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lleida.net (BME:LLN) (EPA:ALLLN) (OTCQX:LLEIF) CEO, Sisco Sapena acquired yesterday 25,000 shares of the company.

Key Points: 
  • MADRID, Spain, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lleida.net (BME:LLN) (EPA:ALLLN) (OTCQX:LLEIF) CEO, Sisco Sapena acquired yesterday 25,000 shares of the company.
  • Sapena, who founded the company in 1995, now controls 34.89% of the Spanish-listed company.
  • This is the second time in the last 30 days that Sapena has bought Lleida.net shares.
  • I trust in the work of the company's team and will bet on them as often as necessary," said Sapena.

Sapena buys 25,000 Lleida.net shares

Retrieved on: 
Thursday, September 1, 2022
Euronext Growth, EPA, OTCQX, CNMV, BME Growth, Union, BME, LLN, GLOBE, Invention, Growth, Subpoena, Online gambling, Renewable energy, Airline

MADRID, Spain, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lleida.net (BME:LLN) (EPA:ALLLN) (OTCQX:LLEIF) CEO, Sisco Sapena acquired yesterday 25,000 shares of the company.

Key Points: 
  • MADRID, Spain, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Lleida.net (BME:LLN) (EPA:ALLLN) (OTCQX:LLEIF) CEO, Sisco Sapena acquired yesterday 25,000 shares of the company.
  • Sapena, who founded the company in 1995, now controls 34.89% of the Spanish-listed company.
  • This is the second time in the last 30 days that Sapena has bought Lleida.net shares.
  • I trust in the work of the company's team and will bet on them as often as necessary," said Sapena.

Bellevue Asset Management AG: Medtech & Services sector lives up to its reputation

Retrieved on: 
Thursday, September 1, 2022
COVID-19, Prospectus, Research, Post office box, Boston Scientific, Medtech, HSG, Population, SICAV, Lux, Risk, EURO STOXX 50, MSCI, Omicron, Danaher, Deloitte, ISIN, Euro, Immunity, Thermo Fisher Scientific, SIX Swiss Exchange, CNMV, Optimism, Association, CHF, Diabetes, Intuitive Surgical, Annual report, Industry, Investment, Judgement, House, Economics, University of St. Gallen, Growth, University, TEL, Life expectancy, AG, Coronavirus, DAX, Human, Stryker, Capital, Radar, Environment, Universal Service Fund, Bank, Insurance

Although the medtech sector is not entirely immune to recessionary forces, inflation or interest rate trends, recent statements from medtech company executives have confirmed that the medtech and services sector can still be regarded as a safe haven in times of trouble.

Key Points: 
  • Although the medtech sector is not entirely immune to recessionary forces, inflation or interest rate trends, recent statements from medtech company executives have confirmed that the medtech and services sector can still be regarded as a safe haven in times of trouble.
  • Looking back at 2008/09, during the last major recession, most medtech companies continued to report positive sales and earnings growth.
  • The Bellevue Medtech & Services Fund (ISIN B-EUR LU0415391431) invests in the entire healthcare market with the exception of drug developers.
  • Marcel Fritsch joined Bellevue Asset Management in 2008 and is Portfolio Manager of the Bellevue Medtech & Services Fund and the Bellevue Digital Health Fund.

Bellevue Asset Management AG: Asia’s rapidly expanding healthcare market

Retrieved on: 
Thursday, August 18, 2022
EPS, Risk, CFA, SIX Swiss Exchange, AG, Research, Prospectus, Patient, Investment, Eyebrow, Multiple myeloma, Lymphatic system, Federal Executive Boards, Board of directors, Technology, Policy, Graubündner Kantonalbank, Post office box, Zurich University, PEG, Public policy, House, Medtech, CHF, Growth, ISIN, COVID, Zurich University of Applied Sciences/ZHAW, Olympus, CNMV, Judgement, Takeda, Lux, Annual report, Association, Health care, SICAV, Johnson & Johnson, Capital, Government, TEL, Daiichi Sankyo, Applied science, Security (finance), Healthcare, Pharmaceutical industry, Fine chemical

Oliver Kubli, Portfolio Manager, Bellevue Asia Pacific Healthcare Fund, Bellevue Asset Management

Key Points: 
  • Oliver Kubli, Portfolio Manager, Bellevue Asia Pacific Healthcare Fund, Bellevue Asset Management
    The healthcare market in emerging Asian economies is a giant growth market.
  • Emerging Asian countries have been particularly active in pursuing sweeping healthcare reforms, in order to keep up with exploding demand.
  • Despite the occasionally brutal stock market sell-offs, Chinese healthcare stocks have outperformed the US stock market by more than 1 000 percent over the past 18 years.
  • About 40% of the Bellevue Asia Pacific Healthcare Fund (ISIN B-USD LU1587984847) is currently invested in China.

ORYZON Collaborates with the CMT Research Foundation in the US

Retrieved on: 
Tuesday, July 26, 2022
People, Sale, Spanish, Multiple sclerosis, GLOBE, ORY, Peripheral nervous system, ISIN, Human, CEO, Forward-looking statement, Research, Person, CNMV, Degenerative disease, Safety, Prospectus, Coronavirus Scientific Advisory Board (Turkey), LSD1, Mission statement, Drug development, Genomics, CMT, Mercado, Charcot–Marie–Tooth disease, Patient, Therapy, Hope, Program, Communication, HDAC6, Public expenditure, Prevalence, Pharmaceutical industry

CMT1A is the most prevalent of all, accounting for approximately half of all people with CMT.

Key Points: 
  • CMT1A is the most prevalent of all, accounting for approximately half of all people with CMT.
  • Oryzon has recently completed an HDAC6 discovery program leading to the selection of two potential preclinical candidates with promising efficacy, selectivity and safety.
  • "We are excited to collaborate with Oryzon on this important project," said Cleary Simpson, CEO of the CMT Research Foundation.
  • The CMT Research Foundation (CMTRF) is focused solely on delivering treatments and cures for CMT.

ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers

Retrieved on: 
Tuesday, July 19, 2022
Research, National, Hematological Cancer Research Investment and Education Act, CRADA, Public expenditure, CEO, ASH, Cancer, Patient, Prospectus, NCI, Person, Squamous cell carcinoma, Safety, Communication, Mission statement, Spanish, NET, Azacitidine, AML, GLOBE, Forward-looking statement, Cooperative research and development agreement, CNMV, LSD1, ALICE, Medulloblastoma, Mercado, FLT3, IND, Development, SCLC, Wilms' tumor, Acute myeloid leukemia, ORY, Sale, ESMO, FDA, ISIN, Genomics, Pharmaceutical industry

Under the terms of the agreement, Oryzon and the NCI will collaborate on potential further clinical development of Oryzons clinical stage LSD1 inhibitor, iadademstat, in different types of solid and hematological cancers.

Key Points: 
  • Under the terms of the agreement, Oryzon and the NCI will collaborate on potential further clinical development of Oryzons clinical stage LSD1 inhibitor, iadademstat, in different types of solid and hematological cancers.
  • Iadademstat is an orally active, highly potent and selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers.
  • More than 100 cancer patients have been treated with iadademstat in several trials.
  • In total iadademstat has been dosed so far to more than 100 cancer patients in four clinical trials.

ORYZON Announces a New Financing Through a Convertible Bond Program for a Total Amount up to €20 Million Over 30 Months

Retrieved on: 
Tuesday, July 5, 2022
Nice, CEO, CN, GLOBE, Â, Public expenditure, Sale, Spanish, ISIN, Prospectus, Genomics, Forward-looking statement, ADR Institute of Alberta, CNMV, Conversion, Mercado, Person, Mission statement, Communication, ORY, Solution, Note, BME, Program, LSD1, Security (finance), Pharmaceutical industry, Nasdaq

The financing program consists of 4 tranches, one tranche of 8 Million and three future optional tranches of 4 Million to be drawn at the discretion of Oryzon, subject to customary conditions.

Key Points: 
  • The financing program consists of 4 tranches, one tranche of 8 Million and three future optional tranches of 4 Million to be drawn at the discretion of Oryzon, subject to customary conditions.
  • The Convertible Notes (CN) have a maturity of 24 months, zero interest rate and have no warrants associated.
  • Oryzon has the right to execute the redemption of any or all Notes at 3% of interest.
  • Nice & Green will have the option to participate in a future capital increase leading to a Nasdaq linked transaction subject to customary conditions.

African stocks markets are stepping out of the shadow of the developed world

Retrieved on: 
Thursday, June 16, 2022
Investment, MSCI, Julius Baer Group, Prospectus, SIX Swiss Exchange, USD, House, Coronavirus, Deutsche Bank, ETH, Swiss, Association, EBITDA, Annual report, Doctor of Philosophy, COVID-19, Lux, EPS, Post office box, CNMV, Capital, Physics, CHF, Risk, TEL, Zurich Insurance Group, Moroccan, Swiss Federal Institute of Aquatic Science and Technology, Research, SICAV, AG, Judgement, Security (finance), Mining, Bank

Selected African markets are particularly well-positioned due to the underlying real economic growth and the forces of structural change.

Key Points: 
  • Selected African markets are particularly well-positioned due to the underlying real economic growth and the forces of structural change.
  • This was especially true in recent years when stocks in the developed world were clearly outperforming emerging market and frontier market stocks on the wings of ultra-loose monetary policy.
  • Major central banks in the developed world really flooded the markets with cash after the outbreak of the coronavirus disease.
  • The Bellevue African Opportunities Fund (+8.3%) outperformed the developed markets (S&P500, +3.2%), emerging markets (MSCI EM, -6.7%) and frontier markets (MSCI Frontier, +2.3%) during the period from September 1, 2021 to April 29, 2022.

ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

Retrieved on: 
Friday, June 10, 2022
Public expenditure, CR, Mission statement, LSD1, NET, Spanish, Safety, ASH, ORR, FLT3, Forward-looking statement, European Hematology Association, ESMO, Mercado, MDR, CNMV, Hematological Cancer Research Investment and Education Act, AML, Person, Financial toxicity, IND, Sale, ISIN, GLOBE, Patient, Acute myeloid leukemia, BCL2, Prospectus, EHA, SCLC, PR, Poster, Communication, ORY, Clinical trial, Population, Squamous cell carcinoma, Medulloblastoma, Azacitidine, Thrombocytopenia, Wilms' tumor, Flow cytometry, ALICE, Cancer, Genomics, Congress, Pharmaceutical industry

Of note, among AML subgroups all evaluable patients with FLT3-ITD (3/3) and 6 of 8 evaluable patients with p53 mutations responded.

Key Points: 
  • Of note, among AML subgroups all evaluable patients with FLT3-ITD (3/3) and 6 of 8 evaluable patients with p53 mutations responded.
  • Dr. Carlos Buesa, Oryzons CEO, said: "These results confirm previous data in supporting a strong synergy between iadademstat and azacitidine in combination.
  • To further investigate the effect in second line, Oryzon is launching FRIDA, a new clinical trial with iadademstat in combination with gilteritinib in FLT3-mutant relapsed/refractory AML patients.
  • In an ongoing Phase IIa trial in elder 1L-AML patients (ALICE trial), iadademstat has shown encouraging safety and efficacy data in combination with azacitidine (see Salamero et al., ASH 2021 poster).